TB-500

Technical specifications

Reference specifications describe the material. They do not replace the analytical results for a specific batch.

Chemical name

Not available

Sequence

Not available

Molecular formula

Not available

Molecular weight

Not available

CAS number

Not available

Form

Lyophilized powder

Appearance

White to off-white solid

Purity specification

Declared in the batch certificate

Identity

Declared in the batch certificate

Solubility

Soluble in sterile water and bacteriostatic water

Storage

−20 °C, protected from light

Stability after reconstitution

Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Batch documentation

Review documentation for the product and variant you are purchasing. A reference specification, a research publication and an individual batch certificate are different sources. Ask support which documents are available for your chosen variant and batch. No analytical result should be assumed from a catalog specification.

Laboratory handling

Reconstitution

Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage

Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment

Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Research references

The name TB-500 does not establish molecular identity. An analytical study identified Ac-LKKTETQ, the 17–23 fragment of thymosin beta-4, in the product it analyzed (PMID 22962027); it does not identify Asciende’s vial. Full-length thymosin beta-4 references provide context and do not establish the effects, composition or equivalence of an uncharacterized commercial material.

1. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

   Drug Test Anal · 2012 · PMID 22962027

2. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

   J Cell Mol Med · 2021 · PMID 34346165

3. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

   Cornea · 2015 · PMID 25826322

4. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing

   Ann N Y Acad Sci · 2007 · PMID 17495250

5. Advances in the basic and clinical applications of thymosin β4

   Expert Opin Biol Ther · 2015 · PMID 26096726

6. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.

   Proc Natl Acad Sci U S A · 1981 · PMID 6940133

7. The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin.

   Eur J Biochem · 1994 · PMID 8055902

Frequently asked questions